Biotechnology company Celyad Oncology (Euronext Brussels:CYAD) announced on Thursday that it has sold its C-Cathez transendocardial catheter to CellProthera, including all intellectual property rights and technical documentation.
The catheter will serve as a core component in CellProthera's upcoming Phase 3 clinical trial, enabling targeted stem cell delivery to damaged cardiac tissue.
The agreement provides for up to EUR5m in milestone-based payments and future royalties on net sales. As the consideration is fully deferred, the transaction will not affect Celyad Oncology's current cash runway, which is expected to last through the third quarter of 2026.
CellProthera is a regenerative cell therapy developer specializing in ischemic diseases, with a leading program in myocardial infarction.
Amgen wins European approval for Uplizna in generalised myasthenia gravis
Celyad Oncology sells C-Cathez catheter to CellProthera
Akeso's AK139 Phase II clinical trials approved in China
Arctic Therapeutics enrols first patients in Phase IIa trial of AT-004 for acne vulgaris
Ribo and Madrigal sign global siRNA licensing deal
Galderma launches Restylane Defyne and Refyne in Japan
Aptamer Optimer technology integrated into Twist Bioscience TrueAmp Library Preparation Kit
AsymBio builds integrated platforms across biopharmaceutical development lifecycle
Evogene expands Google Cloud collaboration to integrate AI agents into ChemPass AI
Cumulus Neuroscience enters Japanese market with Shionogi collaboration
FDA accepts Takeda's oveporexton NDA with priority review for narcolepsy type 1
Eli Lilly signs definitive agreement to acquire Orna Therapeutics
CiteAb launches new scientific image search tool and improved reagent search engine
Innocan Pharma reports findings from clinical study of LPT-CBD in dogs